---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-23-000077"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:10:23.762544+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MacroGenics reports Q1 net loss $38M; cash runway through 2025 on $270M non-dilutive funding

## Summary
- Net loss of $38.0M ($0.61 loss per share) vs. $66.4M loss year ago; revenue $24.5M (up 121% YoY).
- Cash, equivalents & marketable securities $241.7M at March 31, 2023; additional $30M approval milestone from TZIELD received after Q1.
- ZYNYZ (retifanlimab) approved by FDA for MCC; MacroGenics received $15M milestone, eligible for up to $650M more plus tiered royalties.
- Sold TZIELD royalty interest to DRI for $100M upfront; retains 50% share above threshold and up to $430M in Sanofi milestones.
- Phase 2 TAMARACK (vobra duo in mCRPC) enrollment under revised protocol to start Q2 2023; clinical update expected in 2024.

## SEC filing metadata
- accession: 0001125345-23-000077
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/0001125345-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534523000077/mgnx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-23-000077
- JSON: https://secwatch.observer/filing/0001125345-23-000077.json
- Plain text: https://secwatch.observer/filing/0001125345-23-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.